Pathway Diagram
flowchart TD
N0["Proteasome"]
N1["Als"]
N1 -->|"activates"| N0
N2["Neurodegeneration"]
N2 -->|"activates"| N0
N1 -->|"inhibits"| N0
N2 -->|"therapeutic target"| N0
N1 -->|"therapeutic target"| N0
N3["Parkinson"]
N3 -->|"therapeutic target"| N0
N1 -->|"regulates"| N0
N4["AUTOPHAGY"]
N4 -->|"regulates"| N0
N5["UBIQUITIN"]
N5 -->|"regulates"| N0
N4 -->|"activates"| N0
N6["PARKINSON'S DISEASE"]
N6 -->|"therapeutic target"| N0
N2 -->|"therapeutic target"| N0
Experiment Overview Experiment ID : PUMPS-PD-001
Hypothesis : Proteasome-Ubiquitin System Dysfunction Hypothesis in Parkinson's Disease
Primary Objective : Validate that UPS dysfunction is a primary driver of alpha-synuclein aggregation and dopaminergic neurodegeneration in PD
Study Type : Multi-phase translational study (preclinical + clinical)
Study Design
Phase 1: In Vitro Validation (Months 1-6)
1.1 Proteasome Activity Assays Objective : Measure baseline proteasome activity in PD patient-derived cells
Models :
iPSC-derived dopaminergic neurons from PD patients (LRRK2 G2019S,GBA, idiopathic)
Age-matched healthy controls
Isogenic controls with gene corrections
Endpoints :
20S proteasome chymotrypsin-like activity (fluorescent substrate)
20S proteasome trypsin-like activity
20S proteasome caspase-like activity
26S proteasome ATP-dependent activity
Ubiquitin conjugate accumulation (Western blot)
Alpha-synuclein turnover rates (pulse-chase)
...
Pathway Diagram
Mermaid diagram (expand to render)
Experiment Overview Experiment ID : PUMPS-PD-001
Hypothesis : Proteasome-Ubiquitin System Dysfunction Hypothesis in Parkinson's Disease
Primary Objective : Validate that UPS dysfunction is a primary driver of alpha-synuclein aggregation and dopaminergic neurodegeneration in PD
Study Type : Multi-phase translational study (preclinical + clinical)
Study Design
Phase 1: In Vitro Validation (Months 1-6)
1.1 Proteasome Activity Assays Objective : Measure baseline proteasome activity in PD patient-derived cells
Models :
iPSC-derived dopaminergic neurons from PD patients (LRRK2 G2019S,GBA, idiopathic)
Age-matched healthy controls
Isogenic controls with gene corrections
Endpoints :
20S proteasome chymotrypsin-like activity (fluorescent substrate)
20S proteasome trypsin-like activity
20S proteasome caspase-like activity
26S proteasome ATP-dependent activity
Ubiquitin conjugate accumulation (Western blot)
Alpha-synuclein turnover rates (pulse-chase)
Sample Size : n=10 PD iPSC lines, n=10 controls
1.2 Alpha-Synuclein Clearance Kinetics Objective : Determine if UPS impairment specifically affects alpha-synuclein degradation
Methods :
Proteasome inhibition (MG132, bortezomib) dose-response
Alpha-synuclein half-life measurement with cycloheximide chase
Ubiquitination status of alpha-synuclein
Interaction with autophagy compensation
Phase 2: Preclinical Validation (Months 6-12)
2.1 Animal Model Studies Objective : Validate UPS dysfunction as upstream driver in vivo
Models :
A53T alpha-synuclein transgenic mice
UCHL1 mutant mice (UCHL1^S18Y knock-in)
Proteasome hypomorphic mice (PSMA3^D7/D7)
Combination models
Interventions :
Proteasome activators (natural compounds: EGCG, ursolic acid)
Deubiquitinase modulators (UDCA, gene therapy)
Proteasome subunit overexpression
Endpoints :
Behavioral assessment (rotarod, cylinder test, gait analysis)
Proteasome activity in substantia nigra
Alpha-synuclein aggregation (IHC, Western blot)
Dopaminergic neuron survival (TH+ neuron counts)
Motor performance correlation
2.2 Mechanism Validation Objective : Confirm feed-forward loops between UPS dysfunction and alpha-synuclein
Measurements :
Proteasome subunit composition changes
Ubiquitin cascade alterations
Autophagy compensation markers
Mitochondrial function correlation
Phase 3: Clinical Translation (Months 12-24)
3.1 Biomarker Validation Objective : Validate peripheral proteasome activity as PD biomarker
Cohorts :
Early PD (n=100)
Moderate PD (n=100)
Advanced PD (n=100)
Healthy controls (n=100)
Other neurodegenerative disease controls (n=50 each: AD, ALS)
Sample Types :
Peripheral blood mononuclear cells (PBMCs)
CSF proteasome activity
Skin fibroblasts
Exosomes
Endpoints :
PBMC proteasome activity correlation with disease severity
CSF proteasome activity and ubiquitin levels
Predictive value for progression
Specificity for PD vs. other diseases
3.2 Therapeutic Target Engagement Objective : Demonstrate target engagement of proteasome-enhancing interventions
Intervention : Dietary supplementation with proteasome-enhancing compounds
Endpoints :
Peripheral proteasome activity change
Biomarker correlation with motor outcomes
Safety profile
Primary Endpoints | Endpoint | Method | Expected Result |
Secondary Endpoints
Autophagy compensation markers (LC3, p62)
Mitochondrial function (OCR, membrane potential)
Neuroinflammation markers (IL-6, TNF-α in CSF)
Motor function correlation (UPDRS, MoCA)
Statistical Analysis
Primary: t-test/Wilcoxon for proteasome activity (PD vs. controls)
Correlation: Spearman correlation with UPDRS scores
Survival analysis: Cox regression for progression
Power: 80% power to detect 30% reduction at α=0.05
Safety Considerations
Monitor for protein overload toxicity with proteasome activators
Assess hepatic and renal function
Document any unexpected behavioral changes
Budget Estimate | Category | Cost (USD) |
Timeline
Month 1-6 : In vitro experimentsMonth 6-12 : Preclinical animal studiesMonth 12-18 : Clinical biomarker validationMonth 18-24 : Therapeutic pilot studyMonth 24 : Final analysis and publicationSuccess Criteria
Demonstrate >30% reduction in proteasome activity in PD dopaminergic neurons
Show proteasome activity correlates with alpha-synuclein burden
Establish peripheral biomarker with >70% specificity for PD
Identify lead proteasome-enhancing compound for further development
Cross-References
[Parkinson's Disease](/diseases/parkinsons-disease) — Primary disease target
[Alpha-Synuclein Pathway](/mechanisms/alpha-synuclein-pathology) — Aggregation substrate
[Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-system) — UPS mechanism
[LRRK2 Gene](/genes/lrrk2) — LRRK2 G2019S mutation
[GBA Gene](/genes/gba) — GBA mutations, lysosomal dysfunction
[Substantia Nigra](/brain-regions/substantia-nigra) — Affected brain region
[Dopaminergic Neurons](/cell-types/mesencephalic-dopaminergic-neurons) — Target neurons
[Proteasome Activators](/therapeutics/proteasome-activators) — EGCG, ursolic acid
[Autophagy Enhancement](/therapeutics/autophagy-enhancement-therapy) — Compensatory clearance
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-parkinsons) — Convergent pathway
[Neuroinflammation](/mechanisms/neuroinflammation-parkinsons) — Inflammatory cascade
[iPSC Models](/cell-types/ipsc-derived-dopaminergic-neurons) — Disease modeling
[Biomarker Development](/mechanisms/biomarker-development-neurodegeneration) — Peripheral markers
See Also
[Sodium Oligomannate (GV-971) for Alzheimer's Disease](/wiki/therapeutics-sodium-oligomannate-gv971) — regulates
[Ubiquitin](/wiki/proteins-ubiquitin) — binds_to
Show full description